Evicenter
MarkdownMedical informationP&T meetings
Molgramostim Inhalation Solution

Autoimmune pulmonary alveolar proteinosis

Manufacturer
Savara
Launch
Not announced
Last updated
85 sources

Section 6 of 6

References

85 sources

  1. Akasaka et al. (2015) (opens in a new tab)
  2. Alfaro et al. (2025) (opens in a new tab)
  3. Ataya et al. (2025a) (opens in a new tab)
  4. Ataya et al. (2025b) (opens in a new tab)
  5. Bonella and Borie (2025a) (opens in a new tab)
  6. Bonella et al. (2022) (opens in a new tab)
  7. Bonella et al. (2025b) (opens in a new tab)
  8. Bonella et al. (2025c) (opens in a new tab)
  9. Campo et al. (2022) (opens in a new tab)
  10. Campo et al. (2024) (opens in a new tab)
  11. Carey et al. (2022) (opens in a new tab)
  12. CenterWatch (2026) (opens in a new tab)
  13. Chen et al. (2025a) (opens in a new tab)
  14. Chen et al. (2025b) (opens in a new tab)
  15. ClinicalTrials.gov NCT03482752 (opens in a new tab)
  16. ClinicalTrials.gov NCT04544293 protocol (opens in a new tab)
  17. ClinicalTrials.gov NCT04544293 statistical analysis plan (opens in a new tab)
  18. ClinicalTrials.gov NCT06431776 (opens in a new tab)
  19. ClinicalTrials.gov NCT06546098 (opens in a new tab)
  20. CTIS.eu 2024-512039-66-00 (opens in a new tab)
  21. Dang et al. (2026) (opens in a new tab)
  22. European Respiratory Society (opens in a new tab)
  23. FDA Orphan Drug Designations and Approvals (2012) (opens in a new tab)
  24. Futami et al. (2026) (opens in a new tab)
  25. Gajewska et al. (2018) (opens in a new tab)
  26. Guirriec et al. (2024) (opens in a new tab)
  27. Higgins et al. (2026) (opens in a new tab)
  28. Inoue et al. (2008) (opens in a new tab)
  29. Inoue et al. (2026) (opens in a new tab)
  30. Jehn and Bonella (2023) (opens in a new tab)
  31. Jouneau et al. (2025) (opens in a new tab)
  32. Kavuru et al. (2011) (opens in a new tab)
  33. Kim et al. (2022) (opens in a new tab)
  34. Kim et al. (2024) (opens in a new tab)
  35. Lee et al. (2025) (opens in a new tab)
  36. Lettieri et al. (2024) (opens in a new tab)
  37. Loyola Medicine (opens in a new tab)
  38. Luisetti et al. (2011) (opens in a new tab)
  39. Mabo et al. (2023) (opens in a new tab)
  40. McCarthy (2025b) (opens in a new tab)
  41. McCarthy et al. (2018) (opens in a new tab)
  42. McCarthy et al. (2022) (opens in a new tab)
  43. McCarthy et al. (2025a) (opens in a new tab)
  44. McCarthy et al. (2026a) (opens in a new tab)
  45. McCarthy et al. (2026b) (opens in a new tab)
  46. Montaño et al. (2025) (opens in a new tab)
  47. Munsif et al. (2023) (opens in a new tab)
  48. Naeem et al. (2026) (opens in a new tab)
  49. Narita et al. (2026) (opens in a new tab)
  50. National Health Care Institute Horizonscan Geneesmiddelen (2026) (opens in a new tab)
  51. Papiris et al. (2014) (opens in a new tab)
  52. Savara Inc. (2024) (opens in a new tab)
  53. Savara Inc. autoimmune PAP clinical trials page (opens in a new tab)
  54. Savara Inc. autoimmune PAP disease page (opens in a new tab)
  55. Savara Inc. BLA refusal to file announcement (2025) (opens in a new tab)
  56. Savara Inc. BLA resubmission announcement (2025) (opens in a new tab)
  57. Savara Inc. BLA review extension announcement (2026) (opens in a new tab)
  58. Savara Inc. ERS 2026 encore presentations announcement (2026) (opens in a new tab)
  59. Savara Inc. ERS presentation (2019) (opens in a new tab)
  60. Savara Inc. expanded access policy (opens in a new tab)
  61. Savara Inc. Form 10-K (2023) (opens in a new tab)
  62. Savara Inc. Form 10-Q (2026) (opens in a new tab)
  63. Savara Inc. health claims analysis announcement (2025) (opens in a new tab)
  64. Savara Inc. investor relations home page (opens in a new tab)
  65. Savara Inc. MOLBREEVI in autoimmune PAP page (opens in a new tab)
  66. Savara Inc. MOLBREEVI regulatory update announcement (2026) (opens in a new tab)
  67. Savara Inc. NEJM IMPALA-2 publication announcement (2025) (opens in a new tab)
  68. Savara Inc. PANTHERx Rare specialty pharmacy announcement (2026) (opens in a new tab)
  69. Savara Inc. second quarter 2026 results announcement (2026) (opens in a new tab)
  70. Sheng et al. (2018) (opens in a new tab)
  71. Soyez et al. (2018) (opens in a new tab)
  72. Strong et al. (2025) (opens in a new tab)
  73. Tazawa et al. (2019) (opens in a new tab)
  74. Tian et al. (2020) (opens in a new tab)
  75. Trapnell (2024a) (opens in a new tab)
  76. Trapnell and Chowdhury (2022) (opens in a new tab)
  77. Trapnell et al. (2019) (opens in a new tab)
  78. Trapnell et al. (2020) (opens in a new tab)
  79. Trapnell et al. (2024b) (opens in a new tab)
  80. Trapnell et al. (2025a) (opens in a new tab)
  81. Trapnell et al. (2025b) (opens in a new tab)
  82. Trapnell et al. (2026) (opens in a new tab)
  83. Wang et al. (2025) (opens in a new tab)
  84. WHO Collaborating Centre for Drug Statistics Methodology (2026) (opens in a new tab)
  85. Xiong et al. (2026) (opens in a new tab)